<DOC>
	<DOCNO>NCT01265199</DOCNO>
	<brief_summary>The main purpose study determine maximum dose AT-406 safely give combination cytarabine daunorubicin human . Other purpose determine drug break body , see molecular interaction help determine AT-406 work . Side effect also study effort make sure drug safe take .</brief_summary>
	<brief_title>Study Safety , Tolerability , Pharmacokinetics Pharmacodynamic Properties Oral AT-406 Combination With Daunorubicin Cytarabine Patients With Poor-risk Acute Myelogenous Leukemia ( AML )</brief_title>
	<detailed_description>This open label , multi-center , dose escalation study determine MTD oral AT-406 combine daunorubicin cytarabine patient poor-risk AML . Treatment AT-406 administer 60 patient approximately 7 investigational site US . Patients enrol open label sequential cohort 12 patient determine MTD AT-406 combination daunorubicin cytarabine . Dose find occur induction cycle regimen . AT-406 administered consolidation cycle . Patients require re-induction initial treatment remove study replace ( need ) order ass least 3 evaluable patient dose level . Clinical laboratory parameter assess evaluate toxicity AT-406 . In addition , pharmacokinetic ( PK ) pharmacodynamic ( PDy ) blood sample analyze plasma concentration PDy effect AT-406 , respectively .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>Eligibility Criteria : Inclusion : Male female patient age 18 74 Morphological diagnosis untreated relapsed nonM3 AML accord WHO diagnostic criterion exhibit least one poorrisk feature know exhibit favorable cytogenetic feature variant . Patients relapse AML patient prior autologous allogeneic hematopoietic stem cell transplantation eligible relapse occur follow remission ≥ 6 month . Patients must ECOG score ≤ 2 , Adequate cardiac , liver renal function . Exclusion : Must evidence CNS leukemia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>AML</keyword>
</DOC>